STUDY. Outcomes of Primary Cutaneous Squamous Cell Carcinoma With Perineural Invasion

Size: px
Start display at page:

Download "STUDY. Outcomes of Primary Cutaneous Squamous Cell Carcinoma With Perineural Invasion"

Transcription

1 STUDY Outcomes of Primary Cutaneous Squamous Cell Carcinoma With Perineural Invasion An 11-Year Cohort Study Joi B. Carter, MD; Matthew M. Johnson, MD; Tiffany L. Chua, MA, MPH; Pritesh S. Karia, MPH; Chrysalyne D. Schmults, MD, MSCE Objective: To identify factors associated with poor outcomes in perineurally invasive squamous cell carcinoma. Design: Retrospective cohort study. Setting: Two academic hospitals in Boston, Massachusetts. Patients: Adults with perineural SCC diagnosed from 1998 to Main Outcome Measures: Hazard ratios (HRs) for local recurrence, nodal metastasis, death from disease, and overall death, adjusted for known prognostic factors. Results: A total of 114 cases were included, all but 2 involving unnamed nerves. Only a single local recurrence occurred in cases with no risk factors other than nerve invasion. Tumors with large nerve ( 0.1 mm in caliber) invasion were significantly more likely to have other risk factors, including diameters of 2 cm or greater (P.001), invasion beyond the subcutaneous fat (P.003), multiple nerve involvement (P.001), infiltrative growth (P=.01), or lymphovascular invasion (P=.01). On univariate analysis, large nerve invasion was associated with increased risk of nodal metastasis (HR, 5.6 [95% CI, ]) and death from disease (HR, 4.5 [95% CI, ]). On multivariate analysis, tumor diameter of 2 cm or greater predicted local recurrence (HR, 4.8 [95% CI, ]), 1 risk factor predicted nodal metastasis (2 factors: HR, 4.1 [95% CI, ]), lymphovascular invasion predicted death from disease (HR, 15.3 [95% CI, ]), and overall death (HR, 1.1 [95% CI, ]). Invasion beyond subcutaneous fat also predicted overall death (HR, 2.1 [95% CI, ]). Conclusions: Squamous cell carcinoma involving unnamed small nerves ( 0.1 mm in caliber) may have a low risk of poor outcomes in the absence of other risk factors. Large-caliber nerve invasion is associated with an elevated risk of nodal metastasis and death, but this is due in part to multiple other risk factors associated with large-caliber nerve invasion. A larger study is needed to estimate the specific prognostic impact of nerve caliber. JAMA Dermatol. 2013;149(1):35-41 Author Affiliations: Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Carter); Miraca Life Sciences, Newton, Massachusetts (Dr Johnson); and Department of Dermatology, Brigham and Women s Hospital, Harvard Medical School, Boston (Ms Chua, Mr Karia, and Dr Schmults). SQUAMOUS CELL CARCINOMA (SCC) is the second most common type of skin cancer, with approximately new cases of SCC recorded in 2000 in the United States alone. 1 While most SCCs can be cured with excision or Mohs surgery, approximately 5% of all SCCs will metastasize, and the rate of metastasis increases up to 20% in SCCs with high-risk features. 2 Various guidelines delineating these high-risk features have been published based on available data. The American Joint Committee on Cancer (AJCC) published a modified staging system for cutaneous SCC in 2011, which included the following high-risk characteristics that have an impact on tumor stage: depth greater than 2 mm, Clark level IV or greater, perineural invasion, location on ear or vermillion lip, and poorly differentiated or undifferentiated growth pattern on histologic analysis. 2 Perineural invasion (PNI) is one of the new additions to the AJCC staging system and occurs in approximately 2.5% to 5% of primary SCCs. 3,4 Perineural invasion portends poor outcomes with reported risks of lymph node metastasis and distant metastasis of 35% and 15%, respectively, compared with SCC without See Practice Gaps at end of article PNI (in which risks were 15% and 3.3%, respectively in the same study). 5 Squamous cell carcinoma with PNI is also associated with increased mortality. One study reported a 64% 3-year diseasespecific survival for patients with SCC with PNI compared with 91% for SCC without PNI. 6 Previous studies have shown that the extent of nerve invasion has an impact on prognosis. Ross et al 7 found significantly Author Aff Departmen Massachuse Hospital, H School, Bos Miraca Life Massachuse and Depart Dermatolog Women s H Medical Sch (Ms Chua, Dr Schmult 35

2 higher risks of recurrence, metastasis, and diseasespecific mortality in 24 SCCs with PNI of nerves 0.1 mm or greater in diameter compared with 24 SCCs with PNI less than 0.1 mm in diameter. Another study found no difference in 5-year recurrence for 34 SCCs with PNI that are 0.1 mm or smaller vs 28 SCCs with PNI larger than 0.1 mm. 8 However, this study was limited to patients treated with both surgery and radiation, most of whom had positive surgical margins prior to salvage radiation, portending a worse baseline prognosis. The study did find that focal nerve invasion carried a better prognosis than more extensive invasion. Similarly, patients with only microscopic PNI have been shown to have improved local disease control and 10-year survival compared with patients with clinically symptomatic or radiographic perineural invasion Thus, the degree of nerve invasion is likely prognostically important, although optimal classification of varying degrees of invasion remains uncertain. The lack of precise prognostic estimates for SCCs with different degrees of nerve invasion adjusted for other concomitant risk factors prevents clear guidance on the clinical approach to SCC with PNI. This is reflected in heterogeneity of management, as evidenced in a study of Mohs surgeons in which there was little consensus regarding when adjuvant radiation should be used. 12 Clarification of the prognostic significance of different degrees of PNI in combination with other risk factors would aid clinicians in selecting appropriate workup and treatment while minimizing unnecessary treatment and resulting morbidity. This study was undertaken to address the current knowledge gap by comparing outcomes of patients with SCC with large- ( 0.1mm) vs small- ( 0.1 mm) caliber PNI, adjusting for presence of other concomitant prognostic factors via multivariate analysis. METHODS IDENTIFICATION OF COHORT After approval from the Partners Healthcare institutional review board, all patients treated at Massachusetts General Hospital or Brigham and Women s Hospital from January 1, 1998, and December 31, 2008, with pathologically confirmed cutaneous SCC with PNI or neurotropism (NT) were identified via the dermatopathology and surgical pathology databases. The following words contained in the pathology reports were used to search the databases: squamous, nerve, nerves, neural, perineural, neurotropic, and neurotropism. Only patients with PNI in the primary tumor were included. Patients were excluded if the tumor did not have NT or PNI on review by the investigators, if the slides or medical records were not available, if the PNI was identified only in recurrent tumor, or if cutaneous origin of the primary tumor could not be confirmed. MEDICAL RECORD REVIEW Medical records were obtained, and the following information was extracted for each tumor: body location, date of procedure, tumor diameter, preceding scar, preceding radiation therapy, associated symptoms, duration of lesion prior to treatment, dates and methods of all treatments of the primary tumor, as well as any recurrence and/or metastasis, date and type of recurrence (local, in-transit, lymph node, distant organ), and whether a named nerve branch was involved. Patient-specific information was extracted including sex, race/ethnicity, skin cancer history, immunosuppression status, presence of noncutaneous malignant diseases, and, for deceased patients, cause of death as noted in medical records or death certificate. HISTOLOGIC EVALUATION Each case was assigned a study number, and slides were labeled with this unique study number to deidentify them. In a blinded fashion, slides of the tumors were reviewed (by M.M.J., J.B.C., and C.D.S.) for perineural invasion (defined as invasion of the nerve fiber or the presence of neoplastic cells within the perineural space, located between the perineurium and the nerve fiber) or neurotropism (defined as neoplastic cells adjacent to, but not within, the perineural space). Other histologic characteristics of the tumor were recorded, including maximum tumor depth in millimeters as well as by tissue level, involvement of margins on final excision of primary tumor, differentiation of tumor, and presence of lymphatic or vascular invasion. Recorded characteristics of the nerve(s) involved included diameter of the largest involved nerve, number of nerves involved, location of nerve invasion either within the tumor or discontiguous from the tumor, as well as tissue level of the perineural invasion. In cases in which any of this information was ambiguous, a consensus opinion was reached (by J.B.C. and C.D.S.). Both biopsy and excision specimens were evaluated for each primary tumor. Tumors were classified for study analysis according to the greatest degree of nerve involvement seen. STATISTICAL ANALYSIS Cases were assigned to 1 of 2 groups: small-caliber nerve group (PNI of nerves 0.1mm) and large-caliber nerve group (PNI of nerves 0.1 mm). Tests for differences in patient characteristics by nerve caliber group were performed using 2 test for nominal variables and t tests for continuous variables. In analyses with low case numbers of nominal variables, Fisher exact test was used. Large and small nerve caliber groups were compared regarding 4 outcomes of interest (local recurrence [LR], nodal metastasis [NM], death from SCC/disease-specific death [DSD], and all-cause death [ACD]) adjusted for other potential risk factors via multivariate Cox proportional hazard models developed through forward stepwise selection using a stay criterion of.05 or less. Other risk factors included age, sex, immunosuppression, tumor diameter, tumor depth, differentiation, number of nerves involved, lymphovascular invasion, and number of independent prognostic factors present ( Jambusaria-Pahlajani et al 13 ). Each tumor was analyzed as an independent case. Data analysis was performed using SAS statistical software (version 9.2; SAS Institute Inc). All hypothesis tests used a 2-sided significance level of.05. RESULTS PATIENT AND TUMOR CHARACTERISTICS The initial pathology database query identified 164 cases as primary cutaneous SCCs with PNI or NT. Twentythree cases were excluded after histologic review because they had only NT (n=13) or did not have any identifiable PNI or NT (n=10). Of the 141 remaining cases, 15 cases were excluded owing to incomplete slide sets, and 12 cases were excluded owing to insufficient follow-up information in the medical record. The final co- 36

3 Table 1. Tumor Characteristics by Nerve Caliber Group a Tumor Characteristic Large-Caliber (n = 46) Type of PNI, No. (%) Treatment of primary tumor Standard excision 35 (76) 55 (80) Radiation monotherapy 0 1 (1.5) Mohs 6 (9) 11 (16) Other combination therapy 5 (11) 1 (12) Tumor diameter 2 cm 29 (63) 63 (93) 2 cm 17 (37) 5 (7) Tumor differentiation Well 10 (22) 22 (32) Moderate 27 (59) 36 (53) Poor 9 (20) 10 (15) Depth of invasion Dermis 8 (17) 35 (52) Subcutaneous fat 19 (41) 26 (38) Beyond subcutaneous fat 19 (41) 7 (10) Nerves involved, No. 1 9 (20) 45 (66) (52) 19 (28) 5 13 (28) 4 (6) None 39 (85) 67 (99) Location of PNI Intratumor 20 (44) 46 (68) Extratumor 13 (28) 18 (27) Both 13 (28) 4 (6) Infiltrative pattern Yes 32 (70) 31 (46) No 14 (30) 37 (54) Maximal tumor depth 4 mm 5 (11) 24 (35) 4 mm 35 (76) 42 (62) Named nerve involved Yes 2 (4) 0 (0) No 44 (96) 68 (100) Vascular invasion Yes 8 (17) 2 (3) No 38 (83) 66 (97) Lymphatic invasion Yes 7 (15) 1 (2) No 39 (85) 67 (99) Small-Caliber (n = 68) P Value b Abbreviation: PNI, perineural invasion. a Large-caliber PNI: largest nerve invaded by tumor 0.1 mm or greater in diameter; small-caliber PNI: largest involved nerve less than 0.1 mm in diameter. b 2 or Fisher exact test Table 2. Number of Outcome Events by Nerve Caliber Group Outcome of Interest Type of PNI, No. (%) Large-Caliber (n = 46) hort contained 114 cases of primary SCC, with PNI occurring in 96 patients, 46 cases with large-caliber nerve invasion, and 68 with small-caliber nerve invasion. The large-caliber and small-caliber groups were similar in many regards: there was a male predominance (71% male) and mean (SD) age at time of diagnosis was 71 (12) years. All cases occurred in patients identified as white with the exception of a single case in an African American and 5 cases in persons of unknown race. Two cases were in Latinos. Eight patients had more than 1 SCC with PNI. Six of these patients had 2 SCCs with PNI, 1 patient had 3, and a single heart transplant patient had 11 SCCs with PNI. Since the event rate was low in this subgroup (2 LRs and 1 NM occurring in 2 persons, both of whom had 2 SCCs with PNI), each case of SCC with PNI was analyzed independently. Immunostaining (cytokeratin) had been performed in only 4 cases. Two cases involved named nerves, all others involved unnamed nerves. Of 21 cases in which radiologic imaging of the primary tumor was obtained, no case had radiologic evidence of nerve invasion. One patient noted a sharp pain at the site of the tumor. There was no other clinical evidence of nerve invasion. Additional characteristics, including all variables that significantly differed between large- and smallcaliber nerve groups, are summarized in Table 1. Tumors with large-caliber nerve invasion were statistically more likely to have other risk factors than smallcaliber nerve invasion cases, specifically tumor diameter greater than 2 cm (37% vs 7%; P.001), maximum depth of tumor greater than 4 mm (76% vs 62%; P =.003), invasion beyond subcutaneous fat (41% vs 10%; P.001), vascular invasion (17% vs 3%; P =.01) and lymphatic invasion (15% vs 2%; P =.02). They were also more likely to have multiple nerves involved (P.001) and to have nerve involvement both within as well as discontiguous from the tumor (P =.002) (Table 1). Tumors with largercaliber nerve invasion had significantly shorter follow-up time than those with small-caliber invasion (2.7 vs 4.0 years; P =.02), which would tend to underestimate occurrence of poor outcomes in the large-caliber group. However, this difference was adjusted for in Cox models. Thirty-seven SCCs (24% of cases) occurred in immunocompromised patients (27 with organ transplants, 6 with chronic lymphocytic leukemia, 3 with lymphoma, and 1 with human immunodeficiency virus). Immunosuppression was equally common in large- and smallcaliber nerve groups and was not significantly associated with any outcomes of interest on univariate or multivariate modeling. TREATMENT Small-Caliber (n = 68) P Value a Local recurrence 10 (22) 8 (12).15 Nodal metastases 8 (17) 3 (4).03 Death from SCC 6 (13) 2 (3).06 All-cause death 22 (48) 30 (44).70 Abbreviations: PNI, perineural invasion; SCC, squamous cell carcinoma. a Fisher exact test. Treatment of the primary tumor included standard excision (n = 72 cases), standard excision plus radiation (n = 15 cases), standard excision plus lymph node dissection (n = 3 cases), Mohs surgery (n = 15 cases), Mohs surgery plus radiation (n = 2 cases), radiation monotherapy (n = 1 case), electrodessication and curettage (n = 1 case), or other combination therapy (n = 5 cases). Adjuvant radiation was performed in a total of 20 cases (18%) (n = 5 in the smallcaliber nerve invasion group, n = 15 in the large-caliber nerve invasion group). Treatment type was not associated 37

4 Table 3. Number of Outcome Events by Number of Non Perineural Invasion Risk Factors Present a Risk Factors, No. (%) Caliber of PNI, Events (No.) Large (n = 46) Risk factors 8 (17) 12 (26) 18 (39) 8 (17) Local recurrence (n = 10) 0 2 (20) 4 (40) 4 (40) Nodal metastases (n = 8) 0 2 (25) 3 (38) 3 (38) Death from SCC (n = 6) (50) 3 (50) All-cause death (n = 22) 3 (14) 6 (27) 8 (36) 5 (23) Small (n = 68) Risk factors 21 (31) 36 (53) 11 (16) 0 Local recurrence (n = 8) 1 (13) 4 (50) 3 (38) 0 Nodal metastases (n = 3) 0 2 (67) 1 (33) 0 Death from SCC (n = 2) (100) 0 All-cause death (n = 30) 11 (37) 11 (37) 8 (27) 0 Abbreviations: PNI, perineural invasion; RF, risk factor; SCC, squamous cell carcinoma. a Risk factors (not including PNI): moderate or poor tumor differentiation, tumor diameter of at least 2 cm, or depth of invasion beyond subcutaneous fat. Table 4. Unadjusted Hazard Ratios (HRs) Predicting Outcomes of Interest in Univariate Analysis a Local Recurrence Nodal Metastases Death From SCC All-Cause Death Characteristic HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value Age, y 1.0 ( ) ( ) ( ) ( ).001 Sex Female 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] Male 7.8 ( ).046 HR inestimable all... HR inestimable all ( ).21 events in males events in males Nerve caliber involved Small-caliber 1 [Reference] 1 [Reference] 1 [Reference] 1.0 [Reference] Large-caliber 1.9 ( ) ( ) ( ) ( ).18 Tumor diameter 2 cm 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 2 cm 4.8 ( ) ( ) ( ) ( ).005 Tumor differentiation Well 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] Moderate or poor 3.2 ( ).13 HR inestimable all... HR inestimable all ( ).81 events in this group events in this group Named nerve involved No 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] Yes 3.1 ( ) (1-64.1) ( ) ( ).63 Depth of invasion Dermis/subcutaneous 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] fat Beyond subcutaneous 3.1 ( ) ( ) ( ) ( ).09 fat Nerves involved, No. 1 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ).31 Risk factors, No [Reference] 1 [Reference] 1 [Reference] 1 [Reference] ( ) a 4.1 ( ) ( ) ( ) ( ) ( ) ( ).02 Vascular or lymphatic invasion No 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] Yes 2.1 ( ) ( ) ( ) ( ).004 a Risk factors included: moderate or poor tumor differentiation, tumor diameter of at least 2 cm, or depth of invasion beyond subcutaneous fat. b Reference group of 0 to 2 risk factors was used for nodal metastasis outcome only. with differences in outcomes of interest. Of the 17 cases treated with Mohs surgery, 2 had PNI identified during Mohs surgery that had not been identified on initial biopsy. In 1 of these cases, clear margins could not be obtained, and the patient underwent adjuvant radiation. Clear margins were obtained in the other 16 Mohs cases. 38

5 RISK FACTORS FOR OUTCOMES OF INTEREST The overall risks of outcomes of interest were as follows: LR, 16%; NM, 10%; DSD, 7%; and ACD, 46%. Table 2 and Table 3 tabulate the number of events for each outcome by nerve caliber group and by number of non-pni risk factors present (moderate or poor differentiation, diameter 2 cm, or invasion beyond subcutaneous fat). Outcomes were excellent in cases in which PNI was the only risk factor (regardless of nerve caliber) with only a single local recurrence in these 29 cases. On univariate analysis (Table 4), large-caliber nerve invasion was associated with significantly increased risks of NM and DSD (hazard ratio [HR], 5.6 [95% CI, , and HR, 4.5 [95% CI, ], respectively).on multivariate analysis, nerve caliber did not predict any outcome of interest. However, tumor diameter of 2 cm or greater predicted LR (HR, 4.8 [95% CI, ), presence of multiple risk factors predicted NM (2 factors: HR, 4.1 [95% CI, ], and 3 factors: HR, 14.1 [95% CI, ]), and lymphovascular invasion predicted DSD (HR, 15.3 [95% CI, ]) and ACD (HR, 1.1 [95% CI, ]). Invasion beyond subcutaneous fat and older age also predicted ACD (HR, 2.1 [95% CI, ], and HR, 1.1 [95% CI, ], respectively). The results of the multivariate models are summarized in Table 5. COMMENT Perineural invasion of unnamed nerves without other risk factors may have a better prognosis than previously thought. There was only a single local recurrence in this 29-patient subset. Conversely, in cases with other risk factors, a 4- and 14-fold increased risk of nodal metastasis was found in patients with 2 and 3 other risk factors, respectively. Cases with large-caliber nerve invasion were significantly more likely to have other concomitant risk factors, including nerve diameter of 2 cm or greater, invasion beyond the subcutaneous fat or a 4-mm depth, multiple nerve involvement, infiltrative growth, or lymphovascular invasion. Large-caliber nerve invasion was associated with an increased risk of nodal metastasis and death from SCC on univariate analysis. However, on multivariate analysis, other risk factors predominated in predicting poor outcomes, including tumor diameter of 2 cm or greater, presence of more than 1 non-pni risk factor, lymphovascular invasion, and invasion beyond subcutaneous fat. Perineural invasion was recently added to the AJCC SCC staging criteria as a high-risk characteristic. However, there are data to suggest that limited nerve involvement may not have an impact on prognosis as adversely as advanced nerve invasion (Table 6) The findings of this study are consistent with those data, because largecaliber PNI was associated with a 4- to 5-fold increased risk of nodal metastasis and death due to SCC on univariate analysis, indicating that it may be associated with a worse prognosis than small-caliber PNI. Thus, SCC with large-caliber nerve invasion may be considered highrisk, and adjuvant therapy may be considered in such cases. The results further indicate that regardless of nerve Table 5. Adjusted Hazard Ratios (HRs) Predicting Outcomes of Interest in Multivariate Analysis a Outcome HR (95% CI) P Value Local Recurrence Tumor diameter 2 cm 1 [Reference] 2 cm 4.8 ( ).001 Nodal Metastasis Risk factors a [Reference] ( ) ( ).001 Death From SCC Vascular or lymphatic invasion No 1 [Reference] Yes 15.3 ( ).001 All-Cause Death Age 1.1 ( ).001 Vascular or lymphatic invasion No 1 [Reference] Yes 1.1 ( ).004 Depth of invasion Dermis/subcutaneous fat 1 [Reference] Invasion beyond subcutaneous fat 2.1 ( ).04 Abbreviation: SCC, squamous cell carcinoma. a Risk factors included moderate or poor tumor differentiation, tumor diameter of at least 2 cm, or depth of invasion beyond subcutaneous fat. caliber, patients without other risk factors (moderate or poor differentiation, diameter of 2 cm or greater, or tumor penetration beyond subcutaneous fat) have a good prognosis. This is an important finding because it suggests that there are factors other than PNI that may be more robust prognostic indicators. Because largecaliber PNI occurs together with the strong prognostic predictors described herein more often than smallcaliber nerve invasion, it may be a marker for tumors with a particularly poor prognosis owing to the presence of numerous high-risk features. This study was limited to patients diagnosed as having SCC with PNI at 2 academic medical centers. It is possible that there are differences between patients seen at academic centers and those seen elsewhere. However, the study population was confined to those with primary tumors. Thus, the tendency for overestimation of poor outcomes at academic hospitals owing to tertiary care of recurrent tumors was minimized. Although to our knowledge this is the largest cohort study of primary SCC with PNI to date, it was powered only to define the strongest prognostic predictors. A larger study might show that additional risk factors significant on univariate analyses, such as caliber of involved nerves and number of nerves involved, are also independent predictors of outcomes in SCC with PNI. Because only 2 cases in this cohort had invasion of named nerves, the prognosis of this type of extensive PNI could not be fully evaluated. Since prognosis has previously been reported to be poor in patients with involvement of named nerves, named nerve invasion should continue to be regarded as having a high risk of poor outcomes, regardless of presence or absence of other risk factors. 39

6 Table 6. Previous Outcome Studies of Cutaneous Squamous Cell Carcinoma (SCC) With Perineural Invasion (PNI) Source Current study Goepfert et al, Lin et al, Ballantyne et al, Leibovitch et al, Ross et al, McCord et al, and McCord et al, Garcia-Serra et al, Study Description 11-y retrospective cohort of all SCC with PNI at 2 academic hospitals 10-y retrospective cohort of SCC of the head and neck at a single academic hospital 14-y retrospective cohort of SCC with PNI treated with radiation at a single hospital without clinical features Several -year retrospective cohort of head and neck SCC at a single academic hospital 10-y multicenter prospective cohort of SCC treated with Mohs surgery 10-y retrospective cohort of all SCC with PNI at a single academic hospital 30-y retrospective cohort of head and neck BCC and SCC with PNI treated with radiation at a single hospital (IPNI: 31 SCC. Clinical PNI: 46 SCC) 34-y retrospective cohort of head and neck BCC and SCC at a single academic hospital (MPNI: 48 SCCs; clinical PNI: 57 SCCs) Sample Size Primary Recurrent Treatment Excision, Mohs, ± RT Local Recurrence Nodal Metastasis No. (%) Distant Metastasis Disease-Specific Death 18 (16) 11 (10) 1 (2) 8 (7) NR 34 (47) 25 (35) 11 (15) NR Surgery RT, RT alone 5-y RFS PNI 0.1 mm (n = 34); RFS = 77%; 0.1 mm (n = 28); RFS = 86%; unspecific diameter (n = 71); RFS = 75% 6 28 Surgery, RT NR NR NR 53% Mohs, ± RT 2 (8) at 5 y follow-up SCNI a 22 1 LCNI b IPNI CPNI MPNI CPNI Mohs, WLE, ±RT Surgery RT, RT only Surgery RT, RT only SCNI: 2 (9) LCNI: 12 (50) IPNI: 8 (23) CPNI: 29 (47) MPNI: 14% CPNI: 38% None None None SCNI: No events LCNI: 9 (38) IPNI: 1 (3) CPNI: 6 (10) MPNI:14% CPNI: 5% SCNI: No events LCNI: 8 (32) IPNI: 2 (6) CPNI: 1 (2) MPNI: 3% CPNI: 0% SCNI: No events LCNI: 8 (32) IPNI: 26 CPNI: 54 NR Abbreviations: BCC, basal cell carcinoma; CPNI, clinical PNI; IPNI, incidental PNI; MPNI, microscopic PNI; NR, not recorded; RFS, relapse-free survival; RT, radiation therapy; SCC, squamous cell carcinoma; WLE, wide local excision. a Small-caliber nerve invasion ( 0.1 mm in diameter). b Large-caliber nerve invasion ( 0.1 mm in diameter). Because all patients in this study had PNI, the prognostic importance of PNI as a whole, relative to other risk factors, could not be evaluated. In a larger cohort study of SCC outcomes that contains SCC with and without PNI (Schmults et al 15 ), PNI invasion is an independent prognostic factor in multivariate analysis ( Jambusaria- Pahlajani et al 13 ). However, a still-larger, populationbased study of SCC outcomes will likely be necessary to establish the prognostic impact of different gradations of PNI (eg, nerve caliber) in multivariate analysis. Based on the univariate data herein showing good outcomes with small nerve invasion and worse outcomes with large nerve invasion, and other studies that have shown a poor prognosis for patients with SCC with large named nerve or otherwise extensive nerve invasion, it is likely that larger studies will bear out in multivariate modeling that extensive nerve invasion is independently associated with worse outcomes, while lesser nerve invasion is not. Since small-caliber nerve invasion without other risk factors had an excellent prognosis in this study, adjuvant therapy in such cases may not be necessary. In conclusion, SCC invading unnamed nerves of caliber smalller than 0.1 mm without other risk factors may have a good prognosis. However, perineurally invasive SCCs with other risk factors (moderate or poor differentiation, diameter of 2 cm, or deep invasion beyond subcutaneous fat) have a high risk of poor outcomes and may be considered for adjuvant therapy. Large-caliber nerve invasion commonly occurs concomitantly with other risk factors and may therefore be a marker of poor prognosis. Larger studies are needed to estimate the specific prognostic impact of large-caliber nerve invasion on SCC outcomes. Accepted for Publication: June 20, Correspondence: Chrysalyne D. Schmults, MD, MSCE, Mohs and Dermatologic Surgery Center, Department of Dermatology, Brigham and Women s Hospital, 1153 Cen- 40

7 tre St, Ste 4349, Jamaica Plain, MA Author Contributions: Drs Carter and Schmults had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the analysis. Study concept and design: Carter and Schmults. Acquisition of data: Carter, Johnson, Chua, and Karia. Analysis and interpretation of data: Carter, Karia, and Schmults. Drafting of the manuscript: Carter and Karia. Critical revision of the manuscript for important intellectual content: Carter, Johnson, Chua, Karia, and Schmults. Statistical analysis: Karia and Schmults. Administrative, technical, and material support: Carter and Karia. Study supervision: Carter and Schmults. Conflict of Interest Disclosures: None reported. Additional Contributions: We thank Travis Hollmann, MD, PhD, and Victor Neel, MD, PhD. REFERENCES 1. Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005; 294(6): Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011;64(6): Leibovitch I, Huilgol SC, Selva D, Hill D, Richards S, Paver R. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia, II: perineural invasion. J Am Acad Dermatol. 2005;53(2): Mohs FE, Lathrop TG. Modes of spread of cancer of skin. AMA Arch Derm Syphilol. 1952;66(4): Goepfert H, Dichtel WJ, Medina JE, Lindberg RD, Luna MD. Perineural invasion in squamous cell skin carcinoma of the head and neck. Am J Surg. 1984;148 (4): Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23(4): Ross AS, Whalen FM, Elenitsas R, Xu X, Troxel AB, Schmults CD. Diameter of involved nerves predicts outcomes in cutaneous squamous cell carcinoma with perineural invasion: an investigator-blinded retrospective cohort study. Dermatol Surg. 2009;35(12): Lin C, Tripcony L, Keller J, et al. Perineural infiltration of cutaneous squamous cell carcinoma and basal cell carcinoma without clinical features. Int J Radiat Oncol Biol Phys. 2012;82(1): McCord MW, Mendenhall WM, Parsons JT, et al. Skin cancer of the head and neck with clinical perineural invasion. Int J Radiat Oncol Biol Phys. 2000;47 (1): McCord MW, Mendenhall WM, Parsons JT, Flowers FP. Skin cancer of the head and neck with incidental microscopic perineural invasion. Int J Radiat Oncol Biol Phys. 1999;43(3): Garcia-Serra A, Hinerman RW, Mendenhall WM, et al. Carcinoma of the skin with perineural invasion. Head Neck. 2003;25(12): Jambusaria-Pahlajani A, Hess SD, Katz KA, Berg D, Schmults CD. Uncertainty in the perioperative management of high-risk cutaneous squamous cell carcinoma among Mohs surgeons. Arch Dermatol. 2010;146(11): Jambusaria-Pahlajani A, Kanetsky PA, Karia PS, et al. Evaluation of AJCC Tumor (T) Staging for Cutaneous Squamous Cell Carcinoma and a Proposed Alternative Tumor Staging System. JAMA Derm. In Press. 14. Ballantyne AJ. Perineural invasion by SCC. J Dermatol Surg Oncol. 1984;10(7): Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death in cutaneous squamous cell carcinoma: a 10-year single institution study. JAMA Derm. In Press. PRACTICE GAPS Data Needed for Management of Cutaneous Squamous Cell Carcinoma A common task for dermatologists is treatment of primary and/or recurrent cutaneous squamous cell carcinoma (SCC). A biopsy specimen is taken to confirm the diagnosis, and the pathology report is reviewed for prognostic parameters of the tumor, which typically include degree of differentiation and margin involvement but may or may not comment on perineural invasion. Perineural invasion has long been considered to be an adverse prognostic parameter and is found in many other cutaneous malignant tumors, notably basal cell carcinoma, microcystic adnexal carcinoma, and melanoma. In SCC, involvement of large, named nerves documented by clinical signs, symptoms, or radiographic evidence is generally accepted as a significant adverse finding and is usually treated by adjuvant therapy following surgical removal. But what about microscopic nerve involvement seen on the diagnostic biopsy material or subsequent tissue obtained during surgical removal? Carter et al 1 evaluated their experience in 114 cases of SCC with histologically documented perineural invasion managed in 2 academic centers over an 11-year period. They focused on the outcomes of patients with large vs small microscopic nerve involvement (diameter, 0.1 mm vs 0.1 mm) and adjusted for other concomitant prognostic factors. Large-caliber nerve involvement ( 0.1 mm) was found to have an elevated risk of nodal metastasis and death, but these cases were associated with multiple other risk factors. Small-caliber nerve involvement had a much lower adverse risk. The authors advocate for the need of a larger study to fully evaluate the impact of nerve involvement based on size of nerves and number of involved nerves as independent prognostic variables. If we return to our patient with cutaneous SCC, what information do we need to better plan treatment? The list below of adverse prognostic factors in cutaneous SCC shows important adverse prognostic factors 2 and includes documenting the number of nerves involved and caliber of the largest nerve. Anatomic location on ear or nonglabrous lip Tumor size greater than 2 cm 41

8 Tumor thickness greater than 2 mm Clark level of at least 4 Cytologic differentiation classified as poor Perineural involvement classified as more largercaliber nerves than small-caliber nerves It may also be helpful to also document the type of procedure: Mohs vs surgical excision, as en face sectioning allows a much larger examination of the deep margin of the tumor. Standardization of evaluation for nerve involvement would make data more comparable, and there could be documentation of the number of fields examined or the use of double staining for cytokeratin and S100 protein. This is important to ensure that negative nerve involvement is a true finding. Collecting this information in a prospective fashion across multiple sites, both primary and referral, will help provide answers to multiple questions. Should adjuvant therapy be used if perineural invasion is present? Is there a cutoff of nerve caliber? Should a larger excision or an additional Mohs layer be performed if there is nerve involvement? Capturing specific information about tumors in a pathology report in a standardized format will provide the data on which to base recommendations and guidelines for care. Antoinette F. Hood, MD Evan R. Farmer, MD Author Affiliations: Department of Dermatology, Eastern Virginia Medical School, Norfolk (Dr Hood); and Miraca Life Sciences Research Foundation, Irving, Texas (Dr Farmer). Correspondence: Dr Hood, Department of Dermatology, Eastern Virginia Medical School, 721 Fairfax Ave, Norfolk, VA (Hoodaf_194110@evms.edu). Conflict of Interest Disclosures: None reported. 1. Carter JB, Johnson MM, Chua TL, et al. Outcomes of primary cutaneous squamous cell carcinoma with perineural invasion: an 11-year cohort study. JAMA Dermatol. 2013;149(1): Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol. 2011; 64(6): The Best of the Best Top-Accessed Article: Primary Generalized and Localized Hypertrichosis in Children Vashi RA, Mancini AJ, Paller AS. Primary generalized and localized hypertrichosis in children. Arch Dermatol. 2001;137(7): Primary Generalized and Localized Hypertrichosis in Children remains an essential reference for physicians caring for children with primary hypertrichosis. In this article, Vashi and colleagues present a framework for recognizing and classifying primary hypertrichosis and defining patterns and associations. They highlight the limited treatment options and the significance of the psychosocial burden of these disfiguring conditions. As the authors noted, and to this day, the management of hypertrichosis in the pediatric population remains a challenge. Most of the currently available removal options are temporary, uncomfortable, and/or costly. Moreover, there are few data regarding their use in pediatric patients. Over the last decade, there have been significant discoveries relating to the identification of genes expressed in the hair follicle, and knowledge has been gained from families with rare hair disorders. 1 Understanding the potential genetic causes of primary hypertrichosis may provide insight into hair follicle development and normal hair growth, which could lead to improved treatments for this rare disorder. From October 2010 to August 2011, this article was accessed 1997 times on the Archives of Dermatology website. Maria C. Garzon, MD Contact Dr Garzon at the Department of Dermatology, Columbia University, 161 Fort Washington Ave, New York, NY (mcg2@columbia.edu). 1. Shimomura Y, Christiano AM. Biology and genetics of hair. Annu Rev Genomics Hum Genet. 2010;11:

CURRENT ISSUES IN TRANSPLANT DERMATOLOGY

CURRENT ISSUES IN TRANSPLANT DERMATOLOGY CURRENT ISSUES IN TRANSPLANT DERMATOLOGY NO CONFLICTS OF INTEREST TO DISCLOSE SOLID ORGAN TRANSPLANTATION: 2015 As of April 10, 2015.. 123,319 patients waiting for an organ transplant 2,557 performed this

More information

Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma

Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma Evaluation of AJCC, UICC, and Brigham and Women's Hospital Tumor Staging for Cutaneous Squamous Cell Carcinoma Karia, et al Methods Details of data collectionfeatures of primary tumors including anatomic

More information

Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL

Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL on behalf of Dr Louise Lansbury, Prof Fiona Bath-Hextall Nottingham Centre for Evidence Based

More information

Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas

Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas 10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,

More information

Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp

Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp Wray et al. Radiation Oncology (2015) 10:199 DOI 10.1186/s13014-015-0509-2 RESEARCH Open Access Efficacy of elective nodal irradiation in skin squamous cell carcinoma of the face, ears, and scalp Justin

More information

Relevance of the primary lesion in the prognosis of metastatic cutaneous squamous cell carcinoma

Relevance of the primary lesion in the prognosis of metastatic cutaneous squamous cell carcinoma ORIGINAL ARTICLE Relevance of the primary lesion in the prognosis of metastatic cutaneous squamous cell carcinoma Sydney Ch ng, MBBS, FRACS, 1 Jonathan R. Clark, MBBS, FRACS, 1 Markus Brunner, MD, 1 Carsten

More information

RADIOTHERAPY FOR PERINEURAL INVASION IN CUTANEOUS HEAD AND NECK CARCINOMAS: TOWARD A RISK-ADAPTED TREATMENT APPROACH

RADIOTHERAPY FOR PERINEURAL INVASION IN CUTANEOUS HEAD AND NECK CARCINOMAS: TOWARD A RISK-ADAPTED TREATMENT APPROACH ORIGINAL ARTICLE RADIOTHERAPY FOR PERINEURAL INVASION IN CUTANEOUS HEAD AND NECK CARCINOMAS: TOWARD A RISK-ADAPTED TREATMENT APPROACH James E. Jackson, MBBS, 1 Graeme J. Dickie, FRANZCR, 1 Kirsty L. Wiltshire,

More information

Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival

Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS

More information

Modalities of Radiation

Modalities of Radiation Modalities of Radiation Superficial radiotherapy Orthovoltage Megavoltage Photons Electrons Brachytherapy Interstitial Moulds When to refer? The vast majority of skin cancers will be managed without any

More information

SKIN CANCER AFTER HSCT

SKIN CANCER AFTER HSCT SKIN CANCER AFTER HSCT David Rice, PhD, MSN, RN, NP, NEA-BC Director, Education, Evidence-based Practice and Research City of Hope National Medical Center HOW THE EXPERTS TREAT HEMATOLOGIC MALIGNANCIES

More information

46. Merkel Cell Carcinoma

46. Merkel Cell Carcinoma 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

ORIGINAL ARTICLE. Regional Lymph Node Metastasis From Cutaneous Squamous Cell Carcinoma

ORIGINAL ARTICLE. Regional Lymph Node Metastasis From Cutaneous Squamous Cell Carcinoma ORIGINAL ARTICLE Regional Lymph Node Metastasis From Cutaneous Squamous Cell Carcinoma Dennis H. Kraus, MD; John F. Carew, MD; Louis B. Harrison, MD Objective: To characterize clinical presentation and

More information

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.

More information

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy

Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,

More information

Melanoma Update: 8th Edition of AJCC Staging System

Melanoma Update: 8th Edition of AJCC Staging System Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None

More information

Glenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine

Glenn D. Goldman, MD. Fletcher Allen Health Care. University of Vermont College of Medicine Glenn D. Goldman, MD Fletcher Allen Health Care University of Vermont College of Medicine Recognize and identify the main types of skin cancer Understand how and why Mohs surgery is utilized for the treatment

More information

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018

Identifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma

More information

Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD

Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology

More information

For additional information on meeting the criteria for Mohs, see Appendix 2.

For additional information on meeting the criteria for Mohs, see Appendix 2. Position Statement on Appropriate Uses of Paraffin Sections in Association (Approved by the Board of Directors: August 1, 2011; Revised November 5, 2011; Revised August 9, 2014) According to AMA/CPT, Mohs

More information

Glenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine

Glenn D. Goldman, MD. University of Vermont Medical Center. University of Vermont College of Medicine Glenn D. Goldman, MD University of Vermont Medical Center University of Vermont College of Medicine Recognize and identify the main types of skin cancer and their precursors Identify and understand new

More information

Molecular Enhancement of Sentinel Node Evaluation

Molecular Enhancement of Sentinel Node Evaluation Cochran Illustrations 060104 Molecular Enhancement of Sentinel Node Evaluation Alistair Cochran, MD and Rong Huang MD Departments of Pathology and Laboratory Medicine and Surgery, David Geffen School of

More information

Clinical Pathological Conference. Malignant Melanoma of the Vulva

Clinical Pathological Conference. Malignant Melanoma of the Vulva Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge

More information

Epithelial Cancer- NMSC & Melanoma

Epithelial Cancer- NMSC & Melanoma Epithelial Cancer- NMSC & Melanoma David Chin MB, BCh, BAO, LRCP, LRCS (Ireland) MCh(MD), PhD (UQ), FRCS, FRACS (Plast) Plastic & Reconstructive Surgeon Visiting Scientist Melanoma Genomic Group & Drug

More information

Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision

Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate

More information

MOHS MICROGRAPHIC SURGERY: AN OVERVIEW

MOHS MICROGRAPHIC SURGERY: AN OVERVIEW MOHS MICROGRAPHIC SURGERY: AN OVERVIEW SKIN CANCER: Skin cancer is far and away the most common malignant tumor found in humans. The most frequent types of skin cancer are basal cell carcinoma, squamous

More information

Rebecca Vogel, PGY-4 March 5, 2012

Rebecca Vogel, PGY-4 March 5, 2012 Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD

Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do

More information

Human Papillomavirus Testing in Head and Neck Carcinomas

Human Papillomavirus Testing in Head and Neck Carcinomas Human Papillomavirus Testing in Head and Neck Carcinomas Guideline from the College of American Pathologists Early Online Release Publication: Archives of Pathology & Laboratory Medicine 12/18/2017 Overview

More information

Talk to Your Doctor. Fact Sheet

Talk to Your Doctor. Fact Sheet Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent

More information

WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER?

WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? CANCER STAGING TNM and prognosis in CRC WHAT SHOULD WE DO WITH TUMOUR BUDDING IN EARLY COLORECTAL CANCER? Alessandro Lugli, MD Institute of Pathology University of Bern Switzerland Maastricht, June 19

More information

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017

Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed

More information

ORIGINAL RESEARCH. Chance Matthiesen & Spencer Thompson & Salahuddin Ahmad & Elizabeth Syzek & Daniel Zhao & Terence Herman & Carl Bogardus

ORIGINAL RESEARCH. Chance Matthiesen & Spencer Thompson & Salahuddin Ahmad & Elizabeth Syzek & Daniel Zhao & Terence Herman & Carl Bogardus J Radiat Oncol (2013) 2:79 85 DOI 10.1007/s13566-012-0070-7 ORIGINAL RESEARCH A comparison of the sixth and seventh editions of the AJCC TNM systems for T classification and predicting the outcomes of

More information

Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology

Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing

More information

Desmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC

Desmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC R/O BCC Sabine Kohler, M.D. Professor of Pathology and Dermatology Dermatopathology Service Stanford University School of Medicine Clinical Information 74 y.o. man with lesion on left side of neck r/o

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: mohs_micrographic_surgery 07/2004 11/2017 11/2018 11/2017 Description of Procedure or Service Mohs Micrographic

More information

ORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence

ORIGINAL ARTICLE. Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence ORIGINAL ARTICLE Predicting the Prognosis of Oral Squamous Cell Carcinoma After First Recurrence Michael D. Kernohan, FDSRCS, FRCS, MSc; Jonathan R. Clark, FRACS; Kan Gao, BEng; Ardalan Ebrahimi, FRACS;

More information

Summary CHAPTER 1. Introduction

Summary CHAPTER 1. Introduction Summary This thesis aims to evaluate the diagnostic work-up in postmenopausal women presenting with abnormal vaginal bleeding. The Society of Dutch Obstetrics and Gynaecology composed a guideline, which

More information

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report

More information

Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma

Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma ISRN Dermatology Volume 2013, Article ID 586915, 5 pages http://dx.doi.org/10.1155/2013/586915 Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome

More information

Studies of Squamous Cell Carcinoma of the Tongue (TSCC), with Focus on Histological Factors

Studies of Squamous Cell Carcinoma of the Tongue (TSCC), with Focus on Histological Factors Studies of Squamous Cell Carcinoma of the Tongue (TSCC), with Focus on Histological Factors Oskar Jonsson Filip Papic Supervised by Karin Nylander, professor Department of Medical Biosciences Umeå University.

More information

Squamous Cell Carcinoma. Basal Cell Carcinoma. Regional Follow-up Guidelines

Squamous Cell Carcinoma. Basal Cell Carcinoma. Regional Follow-up Guidelines West of Scotland Cancer Network Skin Cancer Managed Clinical Network Squamous Cell Carcinoma Basal Cell Carcinoma Regional Follow-up Guidelines Prepared by Dr M Porter, Dr A Matthews Approved by Skin Cancer

More information

47. Melanoma of the Skin

47. Melanoma of the Skin 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective

Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures

More information

A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study

A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study ORIGINAL ARTICLE A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study Joon-Hyop Lee, MD, Yoo Seung Chung, MD, PhD,* Young Don Lee, MD, PhD

More information

ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma

ORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4

More information

Clinical Study Outcomes of Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma

Clinical Study Outcomes of Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma Skin Cancer Volume 2011, Article ID 972497, 6 pages doi:10.1155/2011/972497 Clinical Study Outcomes of Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma Nichole R. Dean, 1 Larissa Sweeny, 1 J.

More information

Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy

Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)

More information

Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1

Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1 Skin Cancer AMERICAN OSTEOPATHIC COLLEGE OF OCCUPATIONAL & PREVENTIVE MEDICINE OMED 2012 October 8, 2012 E. Robert Wanat II, D.O., M.P.H. Learning Objectives: Identify the 3 Basic Types of Skin Cancer

More information

Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins

Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature. Sasha Jenkins Sentinel Lymph Node Biopsies in Cutaneous Melanoma: A systematic review of the literature By Sasha Jenkins A Master s Paper submitted to the faculty of the University of North Carolina at Chapel Hill in

More information

Controversies and Questions in the Surgical Treatment of Melanoma

Controversies and Questions in the Surgical Treatment of Melanoma Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School

More information

Alcohol should be avoided for 3 days prior to surgery and 2 days after the procedure.

Alcohol should be avoided for 3 days prior to surgery and 2 days after the procedure. Mohs Surgery Information Packet Be sure to bring the following to your appointment: Insurance Card Insurance Referral ( If required by your insurance) Name and address of your primary care provider as

More information

Impact of Prognostic Factors

Impact of Prognostic Factors Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,

More information

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma

More information

Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG

Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the

More information

Update on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017

Update on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017 Update on staging colorectal carcinoma, the 8 th edition AJCC Dale C. Snover, MD November 3, 2017 General overview of staging Reason for uniform staging Requirements to use AJCC manual and/or CAP protocols

More information

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific

More information

Cutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.

Cutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D. Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma

More information

Melanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division

Melanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially

More information

Periocular Malignancies

Periocular Malignancies Periocular Malignancies Andrew Gurwood, O.D., F.A.A.O., Dipl. Marc Myers, O.D., F.A.A.O. Drs. Myers and Gurwood have no financial interests to disclose. Course Description Discussion of the most common

More information

Analysis of the outcome of young age tongue squamous cell carcinoma

Analysis of the outcome of young age tongue squamous cell carcinoma Jeon et al. Maxillofacial Plastic and Reconstructive Surgery (2017) 39:41 DOI 10.1186/s40902-017-0139-8 Maxillofacial Plastic and Reconstructive Surgery RESEARCH Open Access Analysis of the outcome of

More information

Physician to Physician AJCC 8 th Edition. Head and Neck. Summary of Changes. AJCC Cancer Staging Manual, 7 th Ed. Head and Neck Chapters

Physician to Physician AJCC 8 th Edition. Head and Neck. Summary of Changes. AJCC Cancer Staging Manual, 7 th Ed. Head and Neck Chapters Physician to Physician Head and Neck William M. Lydiatt, MD Chair of Surgery Nebraska Methodist Hospital Clinical Professor of Surgery, Creighton University Validating science. Improving patient care.

More information

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB. 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Gene Expression Profiling for Cutaneous Melanoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_expression_profiling_for_cutaneous_melanoma 5/2018

More information

Technicians & Nurses Program

Technicians & Nurses Program ASCRS ASOA Symposium & Congress Technicians & Nurses Program May 6-10, 2016 New Orleans Evaluation and Treatment of Eyelid Malignancies Richard C. Allen MD PhD FACS Professor Section of Ophthalmology Dept.

More information

Upper lip malignant neoplasms. A study of 59 cases

Upper lip malignant neoplasms. A study of 59 cases Med Oral Patol Oral Cir Bucal. 212 May 1;17 (3):e371-6. Journal section: Oral Medicine and Pathology Publication Types: Research doi:1.4317/medoral.1751 http://dx.doi.org/doi:1.4317/medoral.1751 Upper

More information

Skin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice

Skin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice Skin lesions suspicious for melanoma: excision margin guidelines in practice Tess Brian MBBS; 1 Michael B. Jameson MBChB, FRACP, FRCP, PhD 2,3 1 Department of Plastic and Reconstructive Surgery, Waikato

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

Case Report A Rare Cutaneous Adnexal Tumor: Malignant Proliferating Trichilemmal Tumor

Case Report A Rare Cutaneous Adnexal Tumor: Malignant Proliferating Trichilemmal Tumor Case Reports in Medicine Volume 2015, Article ID 742920, 4 pages http://dx.doi.org/10.1155/2015/742920 Case Report A Rare Cutaneous Adnexal Tumor: Malignant Proliferating Trichilemmal Tumor Omer Alici,

More information

Evaluation of AJCC and an Alternative Tumor Classification System for Primary Vulvar Squamous Cell Carcinoma

Evaluation of AJCC and an Alternative Tumor Classification System for Primary Vulvar Squamous Cell Carcinoma Original Research Evaluation of AJCC and an Alternative Tumor Classification System for Primary Vulvar Squamous Cell Carcinoma Sarah T. Le, MBBS (Hons), BMedSci (Hons) a,b ; Pritesh S. Karia, MPH a ; Beverley

More information

Moh's Surgery Information Packet

Moh's Surgery Information Packet Moh's Surgery Information Packet BE SURE TO BRING THE FOLLOWING TO YOUR APPOINTMENT Insurance card Insurance referral (if required by your insurance) Name and address of your primary care provider as well

More information

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases Faruk Tas, Sidika Kurul, Hakan Camlica and Erkan Topuz Institute of Oncology, Istanbul University, Istanbul, Turkey Received

More information

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective

More information

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB.

This form may provide more data elements than required for collection by standard setters such as NCI SEER, CDC NPCR, and CoC NCDB. 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

Michael T. Tetzlaff MD, PhD

Michael T. Tetzlaff MD, PhD Update on American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma Emphasis on concise and accurate reporting of primary and metastatic melanoma for effective risk stratification

More information

What is your diagnosis? Image credits: Eva A. Hurst, MD; Washington University in St. Louis

What is your diagnosis? Image credits: Eva A. Hurst, MD; Washington University in St. Louis Cells to Surgery Quiz: September 2018 Eric P. Sorensen, Jessica B. Dietert, Eva A. Hurst Division of Dermatology, Washington University in St. Louis, Saint Louis, MO, USA What is your diagnosis? Image

More information

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade Quality ID #100 (NQF 0392): Colorectal Cancer Resection Pathology Reporting: pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes) with Histologic Grade National Quality Strategy Domain: Effective

More information

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy. 30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.

More information

6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck

6. Cervical Lymph Nodes and Unknown Primary Tumors of the Head and Neck 1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting

More information

1

1 www.clinicaloncology.com.ua 1 Prognostic factors of appearing micrometastases in sentinel lymph nodes in skin melanoma M.N.Kukushkina, S.I.Korovin, O.I.Solodyannikova, G.G.Sukach, A.Yu.Palivets, A.N.Potorocha,

More information

Prognostic factors for metastatic cutaneous squamous cell carcinoma of the parotid

Prognostic factors for metastatic cutaneous squamous cell carcinoma of the parotid Makki et al. Journal of Otolaryngology - Head and Neck Surgery 2013, 42:14 ORIGINAL RESEARCH ARTICLE Open Access Prognostic factors for metastatic cutaneous squamous cell carcinoma of the parotid Fawaz

More information

Mohs. Micrographic Surgery. For Treating Skin Cancer

Mohs. Micrographic Surgery. For Treating Skin Cancer Mohs Micrographic Surgery For Treating Skin Cancer Skin Cancer Basics Skin cancer is common. Over the past three decades, more people have had skin cancer than all other cancers combined. Each year in

More information

Disclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION

Disclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION 8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,

More information

Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience

Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,

More information

Protocol applies to melanoma of cutaneous surfaces only.

Protocol applies to melanoma of cutaneous surfaces only. Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC

More information

Audit. Public Health Monitoring Report on 2006 Data. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons.

Audit. Public Health Monitoring Report on 2006 Data. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons. National Breast & Ovarian Cancer Centre and Royal Australasian College of Surgeons Audit Public Health Monitoring Report on 2006 Data November 2009 Prepared by: Australian Safety & Efficacy Register of

More information

Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE

Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Controversies in Breast Pathology ELENA PROVENZANO ADDENBROOKES HOSPITAL, CAMBRIDGE Neoadjuvant Chemotherapy Indications: Management of locally advanced invasive breast cancers including inflammatory breast

More information

World Articles of Ear, Nose and Throat Page 1

World Articles of Ear, Nose and Throat Page 1 World Articles of Ear, Nose and Throat ---------------------Page 1 Primary Malignant Melanoma of the Tongue: A Case Report Authors: Nanayakkara PR*, Arudchelvam JD** Ariyaratne JC*, Mendis K*, Jayasekera

More information

A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL

A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of

More information

Journal of International Academy of Forensic Science & Pathology (JIAFP)

Journal of International Academy of Forensic Science & Pathology (JIAFP) Journal of International Academy of Forensic Science & Pathology (JIAFP) ISSN 2395-0722 MICROCYSTIC ADNEXAL CARCINOMA-A CASE REPORT WITH REVIEW OF LITERATURE Case Report Sulakshana M S 1,Natarajan M 2

More information

New and Emerging Therapies: Non-Melanoma Skin Cancers. David J. Goldberg, MD, JD Skin Laser and Surgery Specialists of NY/NJ

New and Emerging Therapies: Non-Melanoma Skin Cancers. David J. Goldberg, MD, JD Skin Laser and Surgery Specialists of NY/NJ New and Emerging Therapies: Non-Melanoma Skin Cancers David J. Goldberg, MD, JD Skin Laser and Surgery Specialists of NY/NJ Disclosure Research Grant form Sensus Superficial Radiation Therapy (SRT) Modern

More information

Melanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU

Melanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma

More information

Iatrogenic Immunosuppression and Cutaneous Malignancy

Iatrogenic Immunosuppression and Cutaneous Malignancy Iatrogenic Immunosuppression and Cutaneous Malignancy Jerry D. Brewer, MD, MS, FAAD brewer.jerry@mayo.edu Professor of Dermatology Chair Division of Dermatologic Surgery Department of Dermatology Mayo

More information

Dermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.

Dermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses. Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.

More information

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female

More information

Mapping Basal Cell and Squamous Carcinoma By 10 Min CK5 Direct Immunohistochemistry on Frozen Section Skin Tissues during Mohs Micrographic Surgery

Mapping Basal Cell and Squamous Carcinoma By 10 Min CK5 Direct Immunohistochemistry on Frozen Section Skin Tissues during Mohs Micrographic Surgery Mapping Basal Cell and Squamous Carcinoma By 10 Min CK5 Direct Immunohistochemistry on Frozen Section Skin Tissues during Mohs Micrographic Surgery Robert Glinert, MD and Song Q. Zhao, MD, Ph.D., MPH Department

More information

INTRODUCTION TO CANCER STAGING

INTRODUCTION TO CANCER STAGING INTRODUCTION TO CANCER STAGING Patravoot Vatanasapt, MD Dept. Otorhinolaryngology Khon Kaen Cancer Registry Faculty of Medicine Khon Kaen University THAILAND Staging is the attempt to assess the size

More information

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER

MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER 10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg

More information

Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]

Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] CS Tumor Size Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] Note: the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the physician's

More information